Nonalcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Its
more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver …

Organoids are three-dimensional (3D) miniature structures cultured in vitro produced from
either human pluripotent stem cells (hPSCs) or adult stem cells (AdSCs) derived from …

The lack of registered drugs for nonalcoholic fatty liver disease (NAFLD) is partly due to the
paucity of human-relevant models for target discovery and compound screening. Here we …

Hepatic, pancreatic, and biliary (HPB) organoids are powerful tools for studying
development, disease, and regeneration. As organoid research expands, the need for clear …

Non-Alcoholic Steatohepatitis (NASH) is the progressive form of Non-Alcoholic Fatty Liver
Disease (NAFLD), the main cause of chronic liver complications. The development of NASH …

Genotype-phenotype associations for common diseases are often compounded by
pleiotropy and metabolic state. Here, we devised a pooled human organoid-panel of …

Metabolic diseases, including obesity, diabetes mellitus and cardiovascular disease, are a
major threat to health in the modern world, but efforts to understand the underlying …

Metabolic dysfunction–associated steatohepatitis (MASH) is a severe form of liver disease
that poses a global health threat because of its potential to progress to advanced fibrosis …

Non-alcoholic fatty liver disease (NAFLD), including non-alcoholic fatty liver (NAFL) and non-
alcoholic steatohepatitis (NASH), represents the hepatic manifestation of obesity and …

The poor predictability of human liver toxicity is still causing high attrition rates of drug
candidates in the pharmaceutical industry at the non-clinical, clinical, and post-marketing …